• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.

作者信息

Li Xuanzong, Sun Jujie, Wang Linlin

机构信息

Department of Radiation Oncology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Department of Pathology Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

出版信息

Clin Lung Cancer. 2021 Sep;22(5):480-481. doi: 10.1016/j.cllc.2021.03.002. Epub 2021 Mar 16.

DOI:10.1016/j.cllc.2021.03.002
PMID:33895104
Abstract
摘要

相似文献

1
NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.NF1 突变型癌症与免疫检查点抑制剂：一项大型数据库分析
Clin Lung Cancer. 2021 Sep;22(5):480-481. doi: 10.1016/j.cllc.2021.03.002. Epub 2021 Mar 16.
2
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.MET突变癌症与免疫检查点抑制剂：一项大型数据库分析
Lung Cancer. 2020 Dec;150:256-258. doi: 10.1016/j.lungcan.2020.09.021. Epub 2020 Sep 30.
3
A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".对《MET突变癌症与免疫检查点抑制剂：一项大型数据库分析》的回复
Lung Cancer. 2020 Dec;150:259-260. doi: 10.1016/j.lungcan.2020.11.001. Epub 2020 Nov 5.
4
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.国家免疫治疗登记处人群水平晚期非小细胞肺癌的检查点抑制剂的疗效。
Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 Dec 28.
5
Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.影像学肿瘤负担与晚期肺癌免疫检查点抑制剂疗效之间缺乏关联。
Oncologist. 2020 Jun;25(6):515-522. doi: 10.1634/theoncologist.2019-0814. Epub 2020 Mar 31.
6
Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.肺癌辅助和新辅助免疫治疗的最新进展和未来展望。
Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187.
7
Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗肺癌患者的反应、无进展生存期和总生存期的预测因素。
J Thorac Oncol. 2021 Jul;16(7):1086-1098. doi: 10.1016/j.jtho.2021.03.017. Epub 2021 Apr 9.
8
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.ROS1 突变型癌症与免疫检查点抑制剂：一项大型数据库分析。
Lung Cancer. 2020 Dec;150:252-253. doi: 10.1016/j.lungcan.2020.08.002. Epub 2020 Aug 5.
9
[Ⅱ. Role of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer].[Ⅱ. 免疫检查点抑制剂在肺癌治疗中的作用]
Gan To Kagaku Ryoho. 2021 Aug;48(8):1023-1026.
10
A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".对《ROS1 突变型癌症与免疫检查点抑制剂：一项大型数据库分析》的回复
Lung Cancer. 2020 Dec;150:254-255. doi: 10.1016/j.lungcan.2020.10.011. Epub 2020 Nov 1.

引用本文的文献

1
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.克服表皮生长因子受体（EGFR）突变型肺癌对奥希替尼耐药的策略
Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.
2
Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers.利用78287例20种癌症患者的临床基因组学数据来表征突变治疗效果。
Nat Commun. 2024 Dec 30;15(1):10884. doi: 10.1038/s41467-024-55251-5.
3
Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
与免疫细胞浸润相关的干扰素调节因子4可预测肺腺癌患者的预后。
Front Oncol. 2021 Jun 14;11:698465. doi: 10.3389/fonc.2021.698465. eCollection 2021.